Steve Kemler

Steve manages the Philadelphia market NetSuite team and provides NetSuite consulting services to a variety of clients in industries including life sciences, technology and wholesale distribution. Steve leads projects that require complex integrations, customizations and complex finance requirements.

As a member of RSM’s life sciences team, Steve consistently supports clients in the industry across the country. He also participates in the PACT MedTech series and is involved in multiple regional life sciences initiatives.

In May 2020, Steve was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves.

5 things to know in life sciences: Week of May 31

Jun. 4, 2021 by Steve Kemler, Adam Lohr, David Stuart and Justin Culbertson

From a new clinical trial service launched by CVS to sequencing the entire human genome, we highlight the latest trends impacting the life sciences industry this week. … READ MORE >

5 things to know in life sciences: Week of May 24

May. 26, 2021 by Steve Kemler, Adam Lohr, David Stuart and Justin Culbertson

This week we highlight the 340B drug pricing program, oncology clinical trials, balancing patient privacy concerns with data needs for artificial intelligence and more. … READ MORE >

5 things to know in life sciences: Week of May 17

May. 21, 2021 by Steve Kemler, Adam Lohr and David Stuart

This week we highlight a new report on COVID-19 trials and diversity; functional service providers; biopharma, drug pricing and ESG scores; and more. … READ MORE >

5 things to know in life sciences: Week of May 10

May. 13, 2021 by Steve Kemler, Adam Lohr and David Stuart

This week we highlight small-company drug launches during the pandemic, the future of the biopharma office, using artificial intelligence to diagnose rare diseases and more. … READ MORE >

5 things to know in life sciences: Week of May 3

May. 7, 2021 by Steve Kemler, Adam Lohr and David Stuart

This week we highlight herd immunity challenges, concerns about waiving patent protections on COVID-19 vaccines, using machine learning to reduce trial risks and more. … READ MORE >

5 things to know in life sciences: Week of April 26

Apr. 30, 2021 by Steve Kemler, Adam Lohr and David Stuart

This week we highlight why people may be skipping their second COVID-19 dose, challenges of AI in patient diagnosis, the evolution of the regulatory environment for biopharma companies and more. … READ MORE >

5 things to know in life sciences: Week of April 19

Apr. 21, 2021 by Adam Lohr, Steve Kemler and David Stuart

This week our senior analysts highlight FDA approval decisions, venture funds focused on life sciences, newly approved remote patient monitoring devices and more. … READ MORE >

5 things to know in life sciences: Week of April 12

Apr. 16, 2021 by Adam Lohr, Steve Kemler and David Stuart

This week we highlight the backstory of challenges that have haunted the AstraZeneca vaccine efforts, machine learning that improves drug delivery, genetically modified mosquitoes and more. … READ MORE >

5 things to know in life sciences: Week of April 5

Apr. 8, 2021 by Steve Kemler

This week we highlight vaccine mandate considerations, the lack of diversity on the boards of life sciences companies, a promising new class of drugs and more. … READ MORE >

5 things to know in life sciences: Week of March 29

Apr. 1, 2021 by Adam Lohr, David Stuart and Steve Kemler

From biopharma merger scrutiny to AI-powered biology research, we highlight what’s happening in the life sciences industry this week. … READ MORE >

« Previous Page